

Paving the future for the treatment of paediatric diseases through a Pan-European Clinical Trials Network









Vision & Mission



Better medicines for babies, children and young people through a pan-European clinical trial network.

c4c will use a coordinated approach to deliver high quality "regulatory grade" clinical trials in:

- Multiple countries
- Multiple sites
- All paediatric age groups

By supporting:

- Trial implementation using resources shared between studies
- Trial design through a combination of information about natural history, feasibility, appropriate innovation, and expert opinion
- Education and awareness within and beyond the network











A pan-EU Paediatric Clinical Trial Network

A project under the EU Innovative Medicines Initiative (IMI)



- Ensure efficacy, safety & quality of health products
- Reduce time to clinical proof of concept
- Improve the current drug development process
- Develop new therapies for diseases with high unmet need & limited market incentives
- Allow engagement in a cross-sector, multi-disciplinary consortium at the forefront of cutting-edge research
- Ensure the voice of patients is heard to safeguard better treatments for children









Key objectives

More efficient trial implementation through the set-up of **national hubs** and qualified sites.

Business cases for sustainability beyond IMI funding



Input in clinical trial design and implementation from pilot expert advisory groups and other fora.

Identification of **Data standards and performance metrics.**

Educational programme for health professionals and awareness raising campaigns for the general public.









Key features

- International network with lean central coordination
- A single point of contact
 - **Efficient** implementation of trials
 - Consistent procedures across sites
 - Strategic and operational feasibility assessment
 - Involvement of experts to develop innovative trial designs & methodology
 - Multi-KEY stakeholder collaboration










Implementation of the project plan











Private-public partnership between Academia and Pharma





























UNIVERSITY OF TARTU





















































































Global Paediatric clinical trials networks











The c4c national Hubs












conect

RECLIP – Spanish Pediatric Clinical Trials Network











RECLIP – Spanish Pediatric Clinical Trials Network

National Institutions

AGENCIA ESPAÑOLA DEL MEDICAMENTO Y PRODUCTOS SANITARIOS



ASOCIACIÓN DE MEDICINA DE LA INDUSTRIA FARMACÉUTICA



ASOCIACIÓN EMPRESARIAL DE LA INDUSTRIA FARMACEUTICA



ASOCIACIÓN ESPAÑOLA DE PEDIATRÍA



International Institutions

Enpr-EMA, Red de Investigación Clínica Pediátrica EMA














General overview of the European context













How c4c will be put to test





- Industry sponsored
- Non-industry-sponsored

Selecting and comparing metrics about studies' start-up and conduct









Expected long term impact of c4c

- Access to new experimental therapies for children in well-designed clinical trials
 - **m** Better training for research personnel and improved trial readiness at all participating sites
 - p | Improved efficiency in executing trials (faster, cheaper)
 - a) Improved data quality for labelling of next generation medicines for children
 - Enhanced role of clinicians and patient/parent advocacy groups in planning and designing studies
- **t** Broadening the access of academic medical centers and clinical faculty across Europe to new experimental therapies









¡GRACIAS POR VUESTRA ATENCIÓN!



Federico Martinón-Torres Cristina Serén Trasorras cristina.seren.trasorras@sergas.es Federico.martinon.torres@sergas.es contact@reclip.org www.conect4children.org www.reclip.org @RECLIPSpain

@fedemartinon









